Renal Cell Carcinoma
First-line systemic therapy in metastatic renal cell carcinoma

Andy (42 years old)

Andy, 42 years old, is a bit of a coffee snob. He is considering moving house to live closer to his favourite coffee place.

He recently presented with haematuria and asthenia.

Assessment summary:

  • CT scan: revealed a left renal mass and diffuse liver lesions, cT3bN0M1
  • Kidney mass biopsy: WHO/ISUP grade 4 clear-cell RCC (ccRCC), sarcomatoid features
  • ECOG PS: 1
  • KPS: 80%
  • No relevant medical history
  • No family history of cancer
  • Blood work:
    • Haemoglobin: 11.2 g/dl (12-13 g/dl)
    • Neutrophils: 8.2x109/l (2.0-7.0x109/l)
    • Platelets: 680x109/l (150-400x109/l)
    • Calcium: 9.0 mg/dl (8.5-10.2 mg/dl)
    • LDH: 420 U/l (135-225 U/l)
  • Liver function tests
    • Alkaline phosphatase: 163 U/l (41-117 U/l)
    • Alanine transaminase (ALT): 22 U/l (7-55 U/l)
    • Aspartate transaminase (AST): 23 U/l (8-48 U/l)
    • Gamma-glutamyl transferase: 46 U/l (5-40 U/l)

Which of the following treatment options would you choose for this patient?